Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MT-125 |
| Synonyms | |
| Therapy Description |
MT-125 is a brain-penetrant small molecule inhibitor of non-muscle myosin II, which potentially induces tumor cell cytotoxicity and decreases tumor growth (PMID: 40499543). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MT-125 | MT 125|MT125 | MT-125 is a brain-penetrant small molecule inhibitor of non-muscle myosin II, which potentially induces tumor cell cytotoxicity and decreases tumor growth (PMID: 40499543). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07185880 | Phase I | MT-125 | A Phase 1 Study of the Safety and Tolerability of MT-125 in GBM Patients (STAR-GBM) | Not yet recruiting | USA | 0 |